MS treatment Zinbryta (daclizumab) withdrawn worldwide amid safety concerns

Disease modifying therapy daclizumab (Zinbryta) has been withdrawn from sale worldwide. Its manufacturers took the decision after reports that a number of people taking the treatment developed serious inflammatory brain disorders. That’s how the news was announced on the MS Society’s website. In the UK, the treatment will no longer be available via the country’s … Continue reading MS treatment Zinbryta (daclizumab) withdrawn worldwide amid safety concerns